Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Blood Pressure and Urinary Protein Excretion Outcomes.
Quick Take: Aliskiren offers a sustained antiproteinuric effect in CKD, potentially useful for ACEi/ARB-intolerant patients, but its blood pressure-lowering is transient, demanding cautious consideration due to limited long-term evidence.
š” Clinical Impact
- Provides a potential alternative for managing proteinuria in chronic kidney disease patients who cannot tolerate standard ACE inhibitor or ARB therapy.
- Emphasizes the need to manage expectations regarding blood pressure control, as its effect is not consistently sustained, and highlights the critical gap in long-term safety and efficacy data.
š Evidence Breakdown
- Evidence Grade: 7/10
- Analysis: This systematic review and meta-analysis evaluated aliskiren monotherapy in CKD patients, demonstrating a consistent reduction in urinary protein excretion. Critically, its observed blood pressure-lowering effect was short-term and lacked sustained significance. The moderate evidence quality, particularly concerning the limited long-term data, warrants circumspection.
š©ŗ Practice Recommendation
Current Status: Niche consideration. Do not use as a first-line agent. May be considered, with significant caution and shared decision-making, for CKD patients with persistent proteinuria who are genuinely intolerant to both ACE inhibitors and ARBs, while actively managing expectations regarding BP control and acknowledging the lack of robust long-term data.